Evaluating the Corrie Lipids Digital Health Program to Improve LDL-Cholesterol Control in Adults at High Cardiovascular Risk

What this Trial Is About

This research aims to evaluate the Corrie Lipids Program, a digital health initiative designed to improve lipid-lowering treatment in adults with uncontrolled LDL cholesterol and high risk of atherosclerotic cardiovascular disease ASCVD. The study focuses on addressing gaps in care by combining a patient smartphone app, clinician education, and integration into clinical workflows. Researchers will assess its impact on LDL cholesterol goal achievement, app use, prescribing patterns, and monitoring using the RE-AIM framework across multiple centers. Participants will receive access to the Corrie Lipids Digital Health Program, which includes a smartphone app providing LDL cholesterol tracking, medication reminders, and educational content. Clinicians also receive training and coaching to support guideline-based lipid management. The study will track outcomes at 6 and 12 months, including LDL cholesterol goal attainment, app engagement, therapy prescribing rates, and clinician program use. During the study, adults will be monitored for LDL cholesterol levels and app usage. Researchers will collect data on prescriptions, lab tests, and clinician involvement in the program. Participants must have a smartphone and be able to use the app. The study will last at least 12 months, with assessments at 6 and 12 months to understand the programs effectiveness, adoption, and maintenance over time.

Impact of the Corrie Lipids Digital Health Program on Lipid Optimization